Invasive fungal infections in transplant recipients

Therapeutic Advances in Infectious Disease

Volumn 1, Issue 3, 2013, Pages 85-105

  Vazquez, Jose A ^a   Miceli, Marisa H ^b   Alangaden, George ^b  

^a Henry Ford Health System Division of Infectious Diseases   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antifungal agents; Aspergillus; Candida; Mucor; transplant recipients

Indexed keywords

EID: 84993813852     PISSN: 20499361     EISSN: 2049937X     Source Type: Journal    
DOI: 10.1177/2049936113491936     Document Type: Review

References (100)

1. Alexander B. Pfaller M. (2006) Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 43: S15–S27.
2. Andes D. Safdar N. Baddley J. Playford G. Reboli A. Rex J. et al (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54: 1110–1122.
3. Ben-Ami R. Lewis R. Kontoyiannis D. (2009) Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr Opin Infect Dis 22: 376–384.
4. Ben-Ami R. Lewis R. Raad I. Kontoyiannis D. (2009) Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 48: 1033–1041.
5. Boudewijns M. Verweij P. Melchers W. (2006) Molecular diagnosis of invasive aspergillosis: the long and winding road. Future Microbiol 1: 283–293.
6. Boutboul F. Alberti C. Leblanc T. Sulahian A. Gluckman E. Derouin F. et al (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 34: 939–943.
7. Campo M. Lewis R. Kontoyiannis D. (2010) Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect 60: 331–337.
8. Chamilos G. Luna M. Lewis R. Bodey G. Chemaly R. Tarrand J. et al (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 91: 986–989.
9. Chandrasekar P. Sobel J. (2006) Micafungin: a new echinocandin. Clin Infect Dis 42: 1171–1178.
10. Charlier C. Hart E. Lefort A. Ribaud P. Dromer F. Denning D. et al (2006) Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 57: 384–410.
11. Colombo A. Nucci M. Park B. Nouér S. Arthington-Skaggs B. da Matta D. et al (2006) Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 44: 2816–2823.
12. Cornely O. Lasso M. Betts R. Klimko N. Vazquez J. Dobb G. et al (2007) Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 60: 363–369.
13. Cortez K. Roilides E. Quiroz-Telles F. Meletiadis J. Antachopoulos C. Knudsen T. et al (2008) Infections caused by Scedosporium spp. Clin Microbiol Rev 21: 157–197.
14. de Pauw B. Walsh T. Donnelly J. Stevens D. Edwards J. Calandra T. et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer / Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46: 1813–1821.
15. Dignani M. Anaissie E. (2004) Human fusariosis. Clin Microbiol Infect 10(Suppl. 1): 67–75.
16. Eiland E. Hassoun A. English T. (2008) Points of concern related to the micafungin versus caspofungin trial. Clin Infect Dis 46: 640–641.
17. Farina C. Gotti E. Suter F. Goglio A. (2006) Scedosporium apiospermum soft–tissue infection: a case report and review of kidney transplant literature. Transplant Proc 38: 1333–1335.
18. Fortún J. Ruiz I. Martín-Dávila P. Cuenca-Estrella M. (2012) Fungal infection in solid organ recipients. Enferm Infecc Microbiol Clin 30(Suppl. 2): 49–56.
19. Freifeld A. Bow E. Sepkowitz K. Boeckh M. Ito J. Mullen C. et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the IDSA. Clin Infect Dis 52: e56–e93.
20. Georgiadou S. Sipsas N. Marom E. Kontoyiannis D. (2011) The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 52: 1144–1155.
21. Herbrecht R. Kessler R. Kravanja C. Meyer M. Waller J. Letscher-Bru V. (2004) Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 23: 1451–1454.
22. Husain S. (2009) Unique characteristics of fungal infections in lung transplant recipients. Clin Chest Med 30: 307–313.
23. Husain S. Alexander B. Munoz P. Avery R. Houston S. Pruett T. et al (2003) Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 37: 221–229.
24. Husain S. Muñoz P. Forrest G. Alexander B. Somani J. Brennan K. et al (2005) Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 40: 89–99.
25. Husain S. Paterson D. Studer S. Pilewski J. Crespo M. Zaldonis D. et al (2006) Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 6: 3008–3016.
26. Ibrahim A. Edwards J. Filler S. Spellberg B. (2011) Mucormycosis and Entomophthoramycosis (zygomycosis). In: Ed. Kaufman C. Pappas P. Sobel J. Dismukes W. (eds) Essentials of Clinical Mycology, 2nd edition. Oxford: Oxford University Press, pp. 265–280.
27. Ibrahim A. Spellberg B. Walsh T. Kontoyiannis D. (2012) Pathogenesis of mucormycosis. Clin Infect Dis 54(Suppl. 1): S16–S22.
28. Kauffman C. (2006) Clinical efficacy of new antifungal agents. Curr Opin Microbiol 9: 1–6.
29. Klont R. Mennink-Kersten M. Verweij P. (2004) Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Dis Infect 39: 1467–1474.
30. Kontoyiannis D. Lewis R. (2006) Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 20: 581–607.
31. Kontoyiannis D. Lewis R. (2011) How I treat mucormycosis. Blood 118: 1216–1224.
32. Kontoyiannis D. Marr K. Park B. Alexander B. Anaissie E. Walsh T. et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50: 1091–1100.
33. Kullberg B. Sobel J. Ruhnke M. Pappas P. Viscoli C. Rex J. et al (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366: 1435–1442.
34. Kuse E. Chetchotisakd P. da Cunha C. Ruhnke M. Barrios C. Raghunadharao D. et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369: 1519–1527.
35. Lamaris G. Chamilos G. Lewis R. Safdar A. Raad I. Kontoyiannis D. (2006) Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989–2006. Clin Infect Dis 43: 1580–1584.
36. Lanternier F. Sun H. Ribaud P. Singh N. Kontoyiannis D. Lortholary O. (2012) Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 54: 1629–1636.
37. Leleu G. Aegerter P. Guidet B. (2002) Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 17: 168–175.
38. Lortholary O. Obenga G. Biswas P. Caillot D. Chachaty E. Bienvenu A. et al (2010) French Mycoses Study Group. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 54: 4446–4450.
39. Maertens J. Buve K. Theunissen K. Meersseman W. Verbeken E. Verhoef G. et al (2009) Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115: 355–362.
40. Maertens J. Lagrou K. Deweerdt H. Surmont I. Verhoef G. Verhaegen J. et al (2000) Disseminated infection by Scedosporium prolificans: an emerging fatality among haematology patients. Case report and review. Ann Hematol 79: 340–344.
41. Maertens J. Verhaegen J. Lagrou K. van Eldere J. Boogaerts M. (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97: 1604–1610.
42. Mennink-Kersten M. Donnelly J. Verweij P. (2004) Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 4: 349–357.
43. Mennink-Kersten M. Verweij P. (2006) Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin N America 20: 711–727.
44. Miceli M. Chandrasekar P. (2012) Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients. Infection and drug resistance. Infect Drug Resist 5: 9–16.
45. Miceli M. Grazziutti M. Woods G. Zhao W. Kocoglu M. Barlogie B. et al (2008) Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 46: 1412–1422.
46. Miceli M. Lee S. (2011) Emerging moulds: epidemiological trends and antifungal resistance. Mycoses 54: e666–e678.
47. Moen M. Lyseng-Williamson K. Scott L. (2009) Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69: 361–392.
48. Morgan J. (2005) Global trends in candidemia: review of reports from 1995–2005. Curr Infect Dis Rep 7: 429–439.
49. Morrell M. Fraser V. Kollef M. (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: potential risk factors for hospital mortality. Antimicrob Agents Chemother 49: 3640–3645.
50. Musk M. Chambers D. Chin W. Murray R. Gabbay E. (2006) Successful treatment of disseminated Scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management. J Heart Lung Transplant 25: 1268–1272.
51. Neofytos D. Fishman J. Horn D. Anaissie E. Chang C. Olyaei A. et al (2010) Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 12: 220–229.
52. Neofytos D. Horn D. Anaissie E. Steinbach W. Olyaei A. Fishman J. et al (2009) Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry. Clin Infect Dis 48: 265–273.
53. Nucci M. (2003) Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 16: 607–612.
54. Nucci M. Anaissie E. (2006) Emerging fungi. Infect Dis Clin North Am 20: 563–579.
55. Nucci M. Anaissie E. (2007) Fusarium infections in immunocompromised patients. Clin Microbiol Rev 20: 695–704.
56. Nucci M. Anaissie E. (2009) Fungal infections in hematopoietic stem cell transplantation and solid–organ transplantation – focus on aspergillosis. Clin Chest Med 30: 295–306.
57. Nucci M. Anaissie E. Queiroz-Telles F. Martins C. Trabasso P. Solza C. et al (2003) Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 98: 315–319.
58. Nucci M. Marr K. Queiroz-Telles F. Martins C. Trabasso P. Costa S. et al (2004) Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 38: 1237–1242.
59. Odabasi Z. Mattiuzzi G. Estey E. et al (2004) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39: 199–205.
60. Pappas P. (2006) Invasive candidiasis. Infect Dis Clin North Am 20: 485–506.
61. Pappas P. Alexander B. Andes D. Hadley S. Kauffman C. Freifeld A. et al (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50: 1101–1111.
62. Pappas P. Kauffman C. Andes D. Benjamin D. Jr Calandra T. Edwards J. Jr et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503–535.
63. Pappas P. Rex J. Lee J. Hamill R. Larsen R. Powderly W. et al (2003) A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37: 634–643.
64. Park B. Pappas P. Wannemuehler K. Alexander B. Anaissie E. Andes D. et al (2011) Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis 17: 1855–1864.
65. Park S. Choi S. Lee D. Choi J. Kim S. Kwon J. et al (2011) Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients. Mycoses 54: 523–530.
66. Pasqualotto A. Colombo A. (2010) Treatment of invasive aspergillosis: a systematic review of randomized clinical trials. Invasive Fungal Inf 4: 18–25.
67. Petrikkos G. Skiada A. Lortholary O. Roilides E. Walsh T. Kontoyiannis D. (2012) Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 54(Suppl. 1): S23–S34.
68. Pfaller M. Diekema D. (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133–163.
69. Pfeiffer C. Fine J. Safdar N. (2006) Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42: 1417–1427.
70. Reboli A. Rotstein C. Pappas P. Chapman S. Kett D. Kumar D. et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356: 2472–2482.
71. Revankar S. Sutton D. (2010) Melanized fungi in human disease. Clin Micro Rev 23: 884–928.
72. Rinaldi M. (1991) Problems in the diagnosis of invasive fungal diseases. Rev Infect Dis 13: 493–495.
73. Rodriguez-Tudela J. Berenguer J. Guarro J. Kantarcioglu A. Horre R. de Hoog G. et al (2009) Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 47: 359–370.
74. Ruhnke M. Bohme A. Buchheidt D. Cornely O. Donhuijsen K. Einsele H. et al (2012) Diagnosis of invasive fungal infections in hematology and oncology – guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 23: 823–833.
75. Sable C. Strohmaier K. Chodakewitz J. (2008) Advances in antifungal therapy. Ann Rev Med 59: 361–379.
76. Safdar N. Smith J. Knasinski V. Sherkow C. Herrforth C. Knechtle S. et al (2010) Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagn Microbiol Infect Dis 66: 7–15.
77. Segal B. Herbrecht R. Stevens D. Ostrosky-Zeichner L. Sobel J. Viscoli C. et al (2008) Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 47: 674–683.
78. Silveira F. Husain S. (2007) Fungal infections in solid organ transplantation. Med Mycol 45: 305–320.
79. Singh N. Avery R. Munoz P. Pruett T. Alexander B. Jacobs R. et al (2003) Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 36: 46–52.
80. Singh N. Husain S. (2003) Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 22: 258–266.
81. Singh N.M., Husain S; AST Infectious Diseases Community of Practice (2013) Aspergillosis in solid organ transplantation. Am J Transplant 13(Suppl 4): 228–241.
82. Singh N. Pruett T. Houston S. Muñoz P. Cacciarelli T. Wagener M. et al (2006) Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl 12: 1205–1209.
83. Sobel J. Revankar S. (2007) Echinocandins – first-choice or first-line therapy for invasive candidiasis? N Engl J Med 356: 2525–2526.
84. Spellberg B. Kontoyiannis D. Fredricks D. Morris M. Perfect J. Chin-Hong P. et al (2012) Risk factors for mortality in patients with mucormycosis. Med Mycol 50: 611–618.
85. Sucher A. Chahine E. Balcer H. (2009) Echinocandins: the newest class of antifungals. Ann Pharmacother 43: 1647–1657.
86. Sulahian A. Boutboul F. Ribaud P. Leblanc T. Lacroix C. Derouin F. (2001) Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 91: 311–318.
87. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al.; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15: 1143–1238.
88. Trifilio S. Bennett C. Yarnold P. McKoy J. Parada J. Mehta J. et al (2007) Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 39: 425–429.
89. Troke P. Aguirrebengoa K. Arteaga C. Ellis D. Heath C. Lutsar I. et al (2008) Global Scedosporium Study Group. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 52: 1743–1750.
90. Ullmann A. Cornely O. (2006) Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis 19: 571–576.
91. van Burik J. Ratanatharathorn V. Stepan D. Miller C. Lipton J. Vesole D. et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39: 1407–1416.
92. Vazquez J. Sobel J. (2006) Anidulafingin: a novel echinocandin. Clin Infect Dis 43: 215–222.
93. Vazquez J. Sobel J. (2011) Candidiasis. In: Ed. Kaufman C. Pappas P. Sobel J. Dismukes W. (eds) Essentials of Clinical Mycology, 2nd edition. Oxford: Oxford University Press, pp. 167–206.
94. Viscoli C. Girmenia C. Marinus A. (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28: 1071–1079.
95. von Eiff M. Roos N. Schulten R. Hesse M. Zuhlsdorf M. van de Loo J. (1995) Pulmonary aspergillosis: early diagnosis improves survival. Resp Internat Rev Thor Dis 62: 341–347.
96. Walsh T. Anaissie E. Denning D. Herbrecht R. Kontoyiannis D. Marr K. et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical infectious diseases. Clin Infect Dis 46: 327–360.
97. Woods G. Miceli M. Grazziutti M. Zhao W. Barlogie B. Anaissie E. (2007) Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 110: 830–834.
98. Xhaard A. Lanternier F. Porcher R. Dannaoui E. Bergeron A. Clement L. et al (2012) Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003–2008). Clin Microbiol Infect 18: E396–E400.
99. Yang Y. (2003) Virulence factors of Candida species. J Microbiol Immunol Infect 36: 223–228.
100. Zou M. Tang L. Zhao S. Zhao Z. Chen L. Chen P. et al (2012) Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PloS ONE 7: e433–e447.